Korean Govt Rejects Industry Call For Price Cut Delay
This article was originally published in PharmAsia News
The South Korean government has decided to push ahead with a drug price cut slated for early 2016 after reviewing the pharma industry's call to postpone the cut by one year. Based on an expert analysis it has conducted, the government concluded that the outbreak of Middle East Respiratory Syndrome (MERS) in the country earlier this year did not have a large impact on pharma firms' revenues.
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.